Correlation of Aqueous, Vitreous, and Serum Protein Levels in Patients With Retinal Diseases.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
01 Nov 2023
Historique:
medline: 7 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: ppublish

Résumé

To further establish aqueous humor (AH) as a clinically suitable source of protein biomarkers in retinal diseases by evaluating the correlation of a large panel of proteins between AH, vitreous humor (VH), and serum (SE). We enrolled 60 subjects (eyes) with various non-infectious retinal diseases. AH, VH, and SE proteins were analyzed using the Olink Target 96 platform (1196 protein assays in total). We compared these three matrices in terms of quantification overlap, principal component analysis, and correlation. In the AH, VH, and SE samples, 841, 917, and 1133 proteins, respectively, were consistently quantified above the limit of detection in more than 30% of patients. AH and VH shared 812 of these proteins. AH and VH samples overlapped along principal component 1, but SE samples were distinct. We identified 490 proteins with significant (false discovery rate [FDR]-adjusted P < 0.05) and relevant correlations (correlation coefficient > 0.5) between AH and VH, compared to only 33 and 40 proteins for VH and SE and for AH and SE, respectively. Due to a close correlation between protein concentrations in the AH and VH and a clear difference from the SE, AH has the potential to serve as a substitute for VH and may hold significance in identifying protein biomarkers and novel targets related to retinal diseases. This study further supports AH as a clinically suitable source of protein biomarkers in retinal diseases. In addition, the identified AH and VH correlations can inform the selection of protein biomarker candidates in future translational research.

Identifiants

pubmed: 37930665
pii: 2792990
doi: 10.1167/tvst.12.11.9
pmc: PMC10629536
doi:

Substances chimiques

Blood Proteins 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9

Références

Transl Vis Sci Technol. 2020 Sep 02;9(10):3
pubmed: 32953243
PLoS One. 2015 May 15;10(5):e0125150
pubmed: 25978536
Eye (Lond). 2023 Aug;37(12):2438-2453
pubmed: 36526863
Diabetes Metab. 2014 Dec;40(6):445-51
pubmed: 24878492
Cell Mol Life Sci. 2022 Dec 31;80(1):22
pubmed: 36585968
Exp Eye Res. 2010 Mar;90(3):376-81
pubmed: 19931527
N Engl J Med. 1994 Dec 1;331(22):1480-7
pubmed: 7526212
Eye (Lond). 2008 Jan;22(1):42-8
pubmed: 16826241
Proteomics Clin Appl. 2015 Feb;9(1-2):187-202
pubmed: 25523418
Am J Ophthalmol. 2007 Jan;143(1):175-6
pubmed: 17188064
Graefes Arch Clin Exp Ophthalmol. 2005 Jan;243(1):3-8
pubmed: 15258777
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
Pharm Res. 2019 Jan 23;36(3):40
pubmed: 30673862
Prog Retin Eye Res. 2016 Jan;50:1-24
pubmed: 26307399
Ophthalmology. 2003 Sep;110(9):1690-6
pubmed: 13129863
Acta Ophthalmol. 2010 Dec;88(8):e311-6
pubmed: 21073666
Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):26
pubmed: 32084272
Front Immunol. 2023 Feb 16;14:1107295
pubmed: 36875133
Br J Ophthalmol. 1997 Nov;81(11):976-9
pubmed: 9505822
Int Ophthalmol. 2020 Feb;40(2):467-475
pubmed: 31802372
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3576-81
pubmed: 11006255
BMC Ophthalmol. 2022 Dec 19;22(1):496
pubmed: 36536319
Curr Eye Res. 2017 Aug;42(8):1202-1208
pubmed: 28497987
J Control Release. 2013 Apr 10;167(1):76-84
pubmed: 23369761
Arch Ophthalmol. 2009 May;127(5):613-21
pubmed: 19433709
Mol Vis. 2011;17:2856-63
pubmed: 22128233
Exp Eye Res. 2016 May;146:107-117
pubmed: 26769219
Int J Mol Sci. 2018 Jun 20;19(6):
pubmed: 29925789
PLoS One. 2021 May 19;16(5):e0248439
pubmed: 34010297
Br J Ophthalmol. 2017 May;101(5):548-550
pubmed: 28100481
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2953-5
pubmed: 19060271
Nanomedicine (Lond). 2013 Dec;8(12):1955-68
pubmed: 23438206
Transl Vis Sci Technol. 2022 Apr 1;11(4):13
pubmed: 35420644
Acta Ophthalmol. 2015 Dec;93(8):e680-1
pubmed: 25833228
Proteomics Insights. 2017 Mar 15;8:1178641816686078
pubmed: 28469465
Br J Ophthalmol. 2014 Jul;98 Suppl 2:ii24-9
pubmed: 24934220
Ophthalmology. 2021 Dec;128(12):1736-1747
pubmed: 34329651
Sci Transl Med. 2012 Aug 29;4(149):149ra119
pubmed: 22932224
Transl Vis Sci Technol. 2019 Nov 01;8(6):1
pubmed: 31695962
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD31-AMD40
pubmed: 30025106
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3553-61
pubmed: 16186333
Eur J Ophthalmol. 2010 Mar-Apr;20(2):402-9
pubmed: 19967679
Ophthalmology. 2006 Feb;113(2):294-301
pubmed: 16406543
Klin Monbl Augenheilkd. 2023 May;240(5):650-661
pubmed: 37207638
Biophys J. 2015 Nov 17;109(10):2171-81
pubmed: 26588575
Am J Physiol. 1987 Jan;252(1 Pt 2):F104-8
pubmed: 3812693

Auteurs

Sabine Wilson (S)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Juliane Siebourg-Polster (J)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Bjoern Titz (B)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Zhiwen Jiang (Z)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Francois Bartolo (F)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
EFOR-CVO et Soladis, Champagne-au-Mont-d'Or, France.

Vincent Lavergne (V)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
EFOR-CVO et Soladis, Basel, Switzerland.

Javier Gayán (J)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Justus G Garweg (JG)

Berner Augenklinik, Bern, Switzerland.
Department of Ophthalmology, Bern University Hospital, University of Bern, Bern, Switzerland.

Sascha Fauser (S)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Andreas Dieckmann (A)

Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH